Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

Alpha-fetoprotein as a Biochemical Marker in Prediction of Placenta Acreta Increta Percreta

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04082507

Enrollment

150

Registered

2019-09-09

Start date

2017-01-01

Completion date

2019-08-30

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta

Brief summary

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Detailed description

in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence of morbid adherent placenta accurately?

Interventions

DIAGNOSTIC_TESTSerum alpha-fetoproteine

Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 39 Years

Healthy volunteers

Inclusion criteria

* pregnant women with history of scarred uterus * plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S * Gestational age from 28wks to full term

Exclusion criteria

* pregnant women with fetus with congenital anomalies * pregnant women with ovarian swelling * pregnant women with medical disease

Design outcomes

Primary

Measure	Time frame	Description
Maternal serum alpha-fetoprotein	From 28weeks to 37 weeks	ng/ml or MOM(Multiple of the median)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026